$2.35
+0.01
(+0.43%)▲
0.85%
Downside
Day's Volatility :3.32%
Upside
2.49%
33.19%
Downside
52 Weeks Volatility :50.32%
Upside
25.63%
Period | Standard Biotools Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -4.1% | 6.5% | 0.0% |
6 Months | -1.27% | 7.1% | 0.0% |
1 Year | -0.43% | 9.8% | 0.0% |
3 Years | -62.5% | 14.2% | -20.2% |
Market Capitalization | 833.4M |
Book Value | $1.23 |
Earnings Per Share (EPS) | -1.0 |
Wall Street Target Price | 3.58 |
Profit Margin | -70.98% |
Operating Margin TTM | -29.42% |
Return On Assets TTM | -9.39% |
Return On Equity TTM | -22.74% |
Revenue TTM | 126.8M |
Revenue Per Share TTM | 0.95 |
Quarterly Revenue Growth YOY | -14.2% |
Gross Profit TTM | -1.4M |
EBITDA | -81.1M |
Diluted Eps TTM | -1.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.05 |
EPS Estimate Next Year | -0.2 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 52.34%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 113.0M | ↑ 10.82% |
Net Income | -59.0M | ↓ 2.51% |
Net Profit Margin | -52.24% | ↑ 7.14% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 117.2M | ↑ 3.79% |
Net Income | -64.8M | ↑ 9.79% |
Net Profit Margin | -55.26% | ↓ 3.02% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 138.1M | ↑ 17.83% |
Net Income | -53.0M | ↓ 18.17% |
Net Profit Margin | -38.38% | ↑ 16.88% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 130.6M | ↓ 5.47% |
Net Income | -59.2M | ↑ 11.73% |
Net Profit Margin | -45.36% | ↓ 6.98% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 97.9M | ↓ 24.99% |
Net Income | -190.1M | ↑ 220.91% |
Net Profit Margin | -194.08% | ↓ 148.72% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 106.3M | ↑ 8.57% |
Net Income | -74.7M | ↓ 60.73% |
Net Profit Margin | -70.21% | ↑ 123.87% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 27.0M | ↑ 5.36% |
Net Income | -20.8M | ↓ 29.16% |
Net Profit Margin | -77.14% | ↑ 37.6% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 25.1M | ↓ 7.04% |
Net Income | -16.8M | ↓ 19.2% |
Net Profit Margin | -67.05% | ↑ 10.09% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 27.7M | ↑ 10.14% |
Net Income | -17.0M | ↑ 1.17% |
Net Profit Margin | -61.59% | ↑ 5.46% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 25.4M | ↓ 8.31% |
Net Income | -21.0M | ↑ 23.22% |
Net Profit Margin | -82.77% | ↓ 21.18% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 28.2M | ↑ 11.12% |
Net Income | -19.8M | ↓ 5.82% |
Net Profit Margin | -70.16% | ↑ 12.61% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 45.5M | ↑ 61.56% |
Net Income | -32.2M | ↑ 62.61% |
Net Profit Margin | -70.61% | ↓ 0.45% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 303.6M | ↑ 5.67% |
Total Liabilities | 231.5M | ↓ 9.7% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 264.8M | ↓ 12.79% |
Total Liabilities | 111.2M | ↓ 51.97% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 324.8M | ↑ 22.64% |
Total Liabilities | 185.7M | ↑ 67.0% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 275.2M | ↓ 15.26% |
Total Liabilities | 180.6M | ↓ 2.74% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 390.3M | ↑ 41.82% |
Total Liabilities | 471.8M | ↑ 161.2% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 323.1M | ↓ 17.23% |
Total Liabilities | 159.9M | ↓ 66.11% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 390.3M | ↓ 5.93% |
Total Liabilities | 471.8M | ↓ 1.23% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 371.7M | ↓ 4.78% |
Total Liabilities | 468.8M | ↓ 0.63% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 355.8M | ↓ 4.26% |
Total Liabilities | 469.2M | ↑ 0.09% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 339.3M | ↓ 4.65% |
Total Liabilities | 471.0M | ↑ 0.38% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 323.1M | ↓ 4.78% |
Total Liabilities | 159.9M | ↓ 66.06% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 777.7M | ↑ 140.71% |
Total Liabilities | 200.4M | ↑ 25.33% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -25.2M | ↑ 4.58% |
Investing Cash Flow | 4.7M | ↓ 73.28% |
Financing Cash Flow | 57.7M | ↑ 98.85% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -35.2M | ↑ 39.72% |
Investing Cash Flow | -39.3M | ↓ 932.82% |
Financing Cash Flow | 2.8M | ↓ 95.16% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -15.4M | ↓ 56.21% |
Investing Cash Flow | 40.0M | ↓ 201.71% |
Financing Cash Flow | 20.9M | ↑ 647.56% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -44.1M | ↑ 185.79% |
Investing Cash Flow | -11.9M | ↓ 129.88% |
Financing Cash Flow | 16.0M | ↓ 23.48% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -89.4M | ↑ 102.83% |
Investing Cash Flow | -88.1M | ↑ 637.71% |
Financing Cash Flow | 230.8M | ↑ 1345.94% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -19.2M | ↓ 22.06% |
Investing Cash Flow | -88.1M | ↓ 920.86% |
Financing Cash Flow | -270.0K | ↑ 5300.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.5M | ↓ 55.76% |
Investing Cash Flow | 43.2M | ↓ 148.97% |
Financing Cash Flow | -2.6M | ↑ 847.41% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -9.3M | ↑ 9.95% |
Investing Cash Flow | 40.1M | ↓ 7.02% |
Financing Cash Flow | -2.1M | ↓ 18.53% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -11.4M | ↑ 22.33% |
Investing Cash Flow | 33.4M | ↓ 16.88% |
Financing Cash Flow | -1.2M | ↓ 44.15% |
Sell
Neutral
Buy
Standard Biotools Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Standard Biotools Inc | 36.05% | -1.27% | -0.43% | -62.5% | -80.35% |
![]() Stryker Corporation | -3.84% | 5.16% | 12.86% | 24.25% | 52.69% |
![]() Boston Scientific Corp. | -3.68% | 21.48% | 41.72% | 68.89% | 76.47% |
![]() Edwards Lifesciences Corp. | -34.8% | -18.49% | -34.85% | -45.17% | -15.86% |
![]() Abbott Laboratories | 1.03% | -5.4% | -7.12% | -11.35% | 20.75% |
![]() Medtronic Plc | -1.99% | -9.34% | -13.21% | -38.74% | -23.49% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Standard Biotools Inc | NA | NA | NA | 0.05 | -0.23 | -0.09 | NA | 1.23 |
![]() Stryker Corporation | 38.91 | 38.91 | 2.92 | 11.95 | 0.19 | 0.07 | 0.01 | 50.33 |
![]() Boston Scientific Corp. | 63.22 | 63.22 | 1.8 | 2.37 | 0.09 | 0.05 | NA | 13.16 |
![]() Edwards Lifesciences Corp. | 36.4 | 36.4 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 33.84 | 33.84 | 5.99 | 4.66 | 0.15 | 0.06 | 0.02 | 22.31 |
![]() Medtronic Plc | 28.97 | 28.97 | 1.52 | 5.2 | 0.07 | 0.04 | 0.04 | 38.29 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Standard Biotools Inc | Buy | $833.4M | -80.35% | NA | -70.98% |
![]() Stryker Corporation | Buy | $129.7B | 52.69% | 38.91 | 16.03% |
![]() Boston Scientific Corp. | Buy | $114.3B | 76.47% | 63.22 | 12.05% |
![]() Edwards Lifesciences Corp. | Buy | $52.4B | -15.86% | 36.4 | 23.74% |
![]() Abbott Laboratories | Buy | $186.6B | 20.75% | 33.84 | 13.65% |
![]() Medtronic Plc | Buy | $102.5B | -23.49% | 28.97 | 11.36% |
Insights on Standard Biotools Inc
Revenue is up for the last 3 quarters, 25.36M → 45.54M (in $), with an average increase of 24.1% per quarter
Netprofit is down for the last 2 quarters, -19.77M → -32.15M (in $), with an average decrease of 62.6% per quarter
In the last 1 year, Boston Scientific Corp. has given 41.7% return, outperforming this stock by 42.1%
In the last 3 years, Boston Scientific Corp. has given 68.9% return, outperforming this stock by 131.4%
fluidigm (nasdaq:fldm) develops, manufactures and markets microfluidic systems for growth markets in the life sciences and in applied markets. fluidigm’s systems consist of instruments, software, integrated fluidic circuits (ifcs), high-performance assays for gene expression and genotyping, and primers for sample preparation for next-generation sequencing. fluidigm technology enables customers to perform thousands of sophisticated biochemical measurements in parallel on samples smaller than the content of a single cell, with nanoliter volumes of reagents, in half the area of a credit card. the company’s integrated customer solutions are designed to significantly simplify experimental workflows, increase throughput and reduce costs while delivering excellent data quality. based in south san francisco, fluidigm offers an exciting and collegial working environment with excellent compensation and benefits, including equity.
Organization | Standard Biotools Inc |
Employees | 534 |
CEO | Dr. Michael Egholm Ph.D. |
Industry | Technology |